C-RQTQ

FILE C-RQTQ·COMPANY·CURATED BY ETERNAL SEARCH

Mogling Bio

Cdc42 inhibition, CASIN, stem cell rejuvenation

modulatingsmall molecule

moglingbio.com·2900 Reading Road Suite #410 Cincinnati OH 45206·Seed·$300K total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-RQTQ

Summary · Eternal Search editorial

Mogling Bio Cdc42 inhibition, CASIN, stem cell rejuvenation

Mogling Bio is developing pharmacological approaches to restore function in aged and exhausted cells, particularly stem cells. Its platform targets age-associated overactivation of Cdc42, aiming to rejuvenate stem cell function and address tissue degeneration and age-related disease. The company describes applications across osteoporosis, immune dysfunction, blood disorders and neurodegeneration.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite34

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Mogling Bio — Early mechanism · Lower middle. Derived deterministically from 25 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (21 programs at preclinical).…

Source: Deterministic

At a glance

Webmoglingbio.com

HQ2900 Reading Road Suite #410 Cincinnati OH 45206

StageSeed

Publications

24 on file

01—Overactivation of Cdc42 GTPase Impairs the Cytotoxic Function of NK Cells From Old Individuals Towards Senescent Fibroblasts—02—Cdc 42 inhibition exerts antiaging-effects on the skin of naturally aging mice—03—Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma—04—Targeting Cdc42 improves motor phenotype in Parkinson’s disease mice and reveals age-dependent susceptibility to α-synuclein—05—Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia—06—Aged murine hematopoietic stem cells drive aging-associated immune remodeling—07—Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms—08—Rejuvenation of Tissue Stem Cells by Intrinsic and Extrinsic Factors—09—Cdc42 inhibition prevents conditioning induced Osteoporosis after stem-cell transplantation—10—Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity—11—Mid-life CDC42 inhibition restores cells of bone remodelling, cytoskeletal architecture and mitochondrial quality to prevent osteoporosis in ageing—12—A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic stem cells—

13—Overactivation of Cdc42 GTPase Impairs the Cytotoxic Function of NK Cells From Old Individuals—

14—Cdc42 inhibition prevents conditioning induced Osteoporosis after stem-cell transplantation—

15—Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma—

16—Targeting Cdc42 improves motor phenotype in Parkinson’s disease mice and reveals age-dependent—

17—Cdc 42 inhibition exerts antiaging-effects on the skin of naturally aging mice—

18—Aged murine hematopoietic stem cells drive aging-associated immune remodeling—

19—Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy—

20—CASin prevents Osteoporosis in normally aging mice—

21—Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia—

22—Rejuvenation of Tissue Stem Cells by Intrinsic and Extrinsic Factors—

23—Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity—

24—A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic—

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Mogling Bio

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.